Melanotan (MT)-II acetate

Melanotan (MT)-II acetate 是一种黑皮质素受体激动剂,可激活黑皮质素受体 3 与黑皮质素受体 4 并刺激中枢内源性催产素的释放,可逆转暴露于短期高脂饮食的斑马鱼出现的识别记忆损伤、焦虑水平升高及探索倾向降低的症状,可改善自闭症谱系障碍小鼠模型中受损的社交行为指标,可诱导体重下降、减少食物摄入并发挥厌食效应,可提高褐家鼠的海绵体内压与勃起活性,可用于记忆损伤、焦虑、探索行为减少、自闭症谱系障碍、肥胖及勃起功能障碍相关研究。
产品编号: MS-I38937 CAS No.: 1036322-26-5 分子式: C52H73N15O11 分子量: 1084.23
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Melanotan (MT)-II acetate 是一种黑皮质素受体激动剂,可激活黑皮质素受体 3 与黑皮质素受体 4 并刺激中枢内源性催产素的释放,可逆转暴露于短期高脂饮食的斑马鱼出现的识别记忆损伤、焦虑水平升高及探索倾向降低的症状,可改善自闭症谱系障碍小鼠模型中受损的社交行为指标,可诱导体重下降、减少食物摄入并发挥厌食效应,可提高褐家鼠的海绵体内压与勃起活性,可用于记忆损伤、焦虑、探索行为减少、自闭症谱系障碍、肥胖及勃起功能障碍相关研究。

生物实验数据

生物活性 Melanotan (MT)-II acetate is a melanocortin receptor agonist that activates melanocortin receptor 3 and melanocortin receptor 4 and stimulates central endogenous oxytocin release, reverses impaired recognition memory, increased anxiety levels, and reduced exploratory tendency in zebrafish exposed to a short-term high-fat diet, ameliorates impaired social behavioral indices in a mouse model of autism spectrum disorder, induces weight loss, reduces food intake, and exerts anorectic effects, increases intracavernosal pressure and erectile activity in Rattus norvegicus, and can be used for research related to memory impairment, anxiety, reduced exploratory behavior, autism spectrum disorder, obesity, and erectile dysfunction.
IC50 & Target

MC3R

 

MC4R

 

体内研究
(In Vivo)

Melanotan (MT)-II (20 μM,经皮浸泡,连续 2 天) acetate 可逆转高脂饮食诱导的斑马鱼识别记忆损伤、探索行为减少及焦虑症状,使这些指标恢复至与正常饮食喂养动物相当的水平。
Melanotan (MT)-II (每日 2.5 μg;颅内脑室注射;持续输注;7 天) acetate 可挽救成年雄性母体免疫激活 (MIA) 小鼠的社交能力缺陷,将社交能力指数评分从 3.1 提升至 26.3。
Melanotan (MT)-II (0.1-1 nM,侧双侧伏隔核微量注射) acetate 可显著减少禁食 C57BL/6J 小鼠长达 24 小时的食物摄入量,产生显著的摄食抑制效果,降低自由进食的小鼠的摄食反应。
Melanotan (MT)-II (0.1-1 mg/kg,静脉注射) acetate 可显著提高清醒大鼠的整体勃起活动,缩短麻醉大鼠首次勃起事件的潜伏期。

Animal Model: Danio rerio, longfin phenotype (3-5 months old, ~50:50 male to female ratio, high-fat diet-induced model)
Dosage: 20 μM
Administration: percutaneous immersion; two days
Result: Reversed the significant reduction in time spent in the red (reinforced) arm of the Y-maze (HF + MT-II group spent significantly more time than untreated HF group, matching control group levels).
Reversed the HF diet-induced increase in time spent in the Y-maze start arm (a marker of anxiety).
Restored total object exploration time in the one-trial memory test to control group levels.
Animal Model: C57BL/6J (4-6 month-old male; maternal immune activation model)
Dosage: 2.5 μg/day
Administration: i.c.v.; continuous infusion; 7 days
Result: Increased sociability index score significantly from 3.1 to 26.3.
Did not produce a significant change in social novelty scores.
Animal Model: C57BL/6J (male, 2-3 months old, average body weight ~22 g, food-deprived for ~16 hours to induce food-motivated state)
Dosage: 0.1, 0.3, 1 nM/side
Administration: bilateral microinjection into nucleus accumbens; single dose
Result: Significantly decreased food intake at 1, 2, and 4 hours post-injection compared to saline.
Significantly decreased food intake at 24 hours post-injection only at 0.3 nmol/side dose compared to saline.
Showed a significant main effect of drug, time, and drug-time interaction.
Animal Model: Sprague-Dawley (male, 225-250 g, telemetric intracavernosal pressure monitoring model)
Dosage: 0.1 mg/kg; 0.3 mg/kg; 1 mg/kg
Administration: i.v.
Result: Induced at least one penile erection in 4 out of 5 rats, with a mean 1.6 erections, mean latency to first erection of 2812 s, mean ICPmax of ~360 mmHg, mean AUC of ~2100 mmHg.s, and mean SUM AUC of ~3000 mmHg.s at 0.1 mg/kg.
Induced at least one penile erection in 4 out of 6 rats, with a mean 1.8 erections, mean latency to first erection of 2616 s, mean ICPmax of 472 mmHg, mean AUC of ~2200 mmHg.s, and mean SUM AUC of ~4000 mmHg.s at 0.3 mg/kg.
Induced at least one penile erection in 6 out of 8 rats, with a mean 4.8 erections, mean latency to first erection of 1780 s, mean ICPmax of 548 mmHg, mean AUC of ~2300 mmHg.s, and mean SUM AUC of 10653 mmHg.s at 1 mg/kg.

化学信息

分子量 1084.23
分子式 C52H73N15O11
CAS No. 1036322-26-5

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础